Table 3.
Frequency of systemic manifestations between males and females of the study population
| Systemic manifestations | n (%) | Male n (%) | Female n (%) | P |
|---|---|---|---|---|
| Tuberculosis* | 229 (22.8) | 182 (23.9) | 47 (19.3) | 0.137 |
| Syphilis* | 178 (17.7) | 155 (20.4) | 23 (9.5) | <0.001 |
| Pneumocystis pneumonia * | 162 (16.2) | 132 (17.4) | 30 (12.3) | 0.064 |
| Herpes zoster* | 149 (7.4) | 122 (16.1) | 27 (11.1) | 0.059 |
| Herpes simplex* | 124 (12.4) | 91 (12.0) | 33 (13.6) | 0.508 |
| Toxoplasmosis* | 101 (10.1) | 75 (9.9) | 26 (10.7) | 0.708 |
| Kaposi Sarcoma† | 55 (5.5) | 53 (7.0) | 2 (0.8) | <0.001 |
| Cytomegalovirus† | 52 (5.2) | 46 (6.1) | 6 (2.5) | 0.016 |
| Cryptococcosis† | 21 (2.1) | 13 (1.7) | 8 (3.3) | 0.194 |
| Primary lymphoma of the CNS† | 19 (1.9) | 13 (1.7) | 6 (2.5) | 0.426 |
CNS, central nervous system.
*
Chi-square test.
†
Fisher’s exact test.